Premium
MCM 7 expression predicts post‐operative prognosis for hepatocellular carcinoma
Author(s) -
Zhou YanMing,
Zhang XiaoFeng,
Cao Lu,
Li Bin,
Sui ChengJun,
Li YuMin,
Yin ZhengFeng
Publication year - 2012
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/j.1478-3231.2012.02846.x
Subject(s) - sorafenib , hepatocellular carcinoma , immunohistochemistry , medicine , oncology , metastasis , cancer research , clinical significance , overall survival , pathology , cancer
Background Dysregulation of minichromosome maintenance protein 7 ( MCM 7) was previously identified in multiple human malignancies. The clinical significance of MCM 7 expression is yet to be delineated in patients with hepatocellular carcinoma ( HCC ). Methods Paired cancerous and non‐cancerous specimens from 87 patients with HCC who underwent resection were used for the immunohistochemical evaluation of MCM 7 expression. Effect of sorafenib on the expression of MCM 7 was tested in two human HCC cell lines SMMC ‐7721 and PLC/PRF/5 . Results Non‐cancerous tissues were negative for immunohistochemical staining for MCM 7 expression. Nuclear MCM 7 was expressed in 42 of 87 HCC (48.2%) and was correlated with hepatitis B virus infection ( P = 0.020), intrahepatic metastasis ( P = 0.022) and vascular invasion ( P = 0.013). Moreover, its expression was correlated with shorter overall survival ( P = 0.033). Multivariate analysis showed that MCM 7 expression was an independent prognostic factor for overall survival( P = 0.041). Sorafenib inhibited the expression of MCM 7 in a concentration‐dependent manner in vitro . Conclusions The current findings suggested that MCM 7 expression may be a useful predictor of prognosis in patients with HCC after resection. Adjuvant therapy with sorafenib might be a valuable therapeutic strategy for MCM 7‐positive HCC patients.